ASSESSMENT OF PATIENT'S RADIATION EXPOSURES RESULTED FROM PET/CT 18F-FCH AND 68GA-PSMA PROCEDURES

Salah H 1 , Al-Mohammed HI 2 , Mayhoub FH 3 , Sulieman A 4 , Alkhorayef M 5 , Abolaban FA 6 Show all authors , Khandaker MU 7 , Bradley DA 8

Affiliations 

  • 1 INAYA Medical Collage, Nuclear Medicine Department, P.O. Box 271880, Riyadh 11352, Saudi Arabia
  • 2 Department of Radiological Sciences, College of Health and Rehabilitation Sciences, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671 Saudi Arabia
  • 3 Department of Biomedical Physics, King Faisal Specialist Hospital & Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia
  • 4 Prince Sattam Bin Abdulaziz University, College of Applied Medical Sciences, Radiology and Medical Imaging Department, P.O.Box 422, Alkharj 11942, Saudi Arabia
  • 5 Department of Radiological Sciences, College of Applied Medical Sciences, King Saud University, P.O.Box 10219, Riyadh 11433, Saudi Arabia
  • 6 Nuclear Engineering Department, Faculty of Engineering, King Abdulaziz University, P. O. Box 80221, Jeddah 21589, Saudi Arabia
  • 7 Centre for Biomedical Physics, School of Healthcare and Medical Sciences, Sunway University, 47500 46150 PJ, Bandar, No. 5, Jalan Universiti, Sunway, Selangor Darul Ehsan, Malaysia
  • 8 Centre for Nuclear and Radiation Physics, Department of Physics, University of Surrey, Guildford GU2 7XH, UK
Radiat Prot Dosimetry, 2021 Oct 12;195(3-4):349-354.
PMID: 34144608 DOI: 10.1093/rpd/ncab077

Abstract

This study has sought to evaluate patient exposures during the course of particular diagnostic positron emission tomography and computed tomography (PET/CT) techniques. A total of 73 patients were examined using two types of radiopharmaceutical: 18F-fluorocholine (FCH, 48 patients) and 68Ga-prostate-specific membrane antigen (PSMA, 25 patients). The mean and range of administered activity (AA) in MBq, and effective dose (mSv) for FCH were 314.4 ± 61.6 (462.5-216.8) and 5.9 ± 1.2 (8.8-4.11), respectively. Quoted in the same set of units, the mean and range of AA and effective dose for 68Ga-PSMA were 179.3 ± 92.3 (603.1-115.1) and 17.9 ± 9.2 (60.3-11.5). Patient effective doses from 18F-FCH being a factor of two greater than the dose resulting from 68Ga-PSMA PET/CT procedures. CT accounts for some 84 and 23% for 18F-FCH and 68Ga-PSMA procedures, accordingly CT acquisition parameter optimization is recommended. Patient doses have been found to be slightly greater than previous studies.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications